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Abstract: 
The purpose of this study was to assess primary care physicians’ awareness, experience, opinions 
and preparedness to answer patients’ questions regarding direct-to-consumer (DTC) genetic 
testing. An anonymous survey was mailed to 2,402 family and internal medicine providers in 
North Carolina. Of the 382 respondents, 38.7% (n = 148) were aware of and 15% (n = 59) felt 
prepared to answer questions about DTC genetic tests. Respondents aged 50 or older were more 
likely to be aware of DTC genetic testing than those less than 40 years old (OR = 2.42). Male 
providers were more likely to feel prepared to answer questions than female providers 
(OR = 2.65). Among respondents who reportedly were aware, family practitioners were more 
likely than internists (OR = 3.30) to think DTC testing was clinically useful, and 18.9% had 
patients ask questions or bring in test results. The small percent of physicians who were aware of 
DTC genetic testing or felt prepared to answer questions about it suggests that education of 
providers will be necessary if testing becomes more widespread. 
Direct-to-consumer | Genetic testing | Primary care providers | Genetic susceptibility Keywords: 
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Article: 
Introduction 
Personal genome tests that use variants identified by genome wide association studies (GWAS) 
to assess risk for disease have been offered directly to the consumer over the internet since 2007 
(Offit 2008). There have been discussions within the medical community concerning personal 
genome testing including: 1) the questionable clinical utility of GWAS tests, 2) the inability to 
determine absolute disease risk from GWAS data, 3) the absence of specific health 
recommendations based on the genotypic results of these tests, 4) inadequate informed consent 
prior to testing, 5) limited explanation of test results, and 6) whether personal genome tests are 
valid and reliable in comparison to genetic tests that are administered and regulated under the 
supervision of healthcare providers (Evans and Green 2009; Gross et al. 2009; Kutz 2010; 
Swan 2010). 
Personal genome testing companies screen for risks of serious diseases such as heart disease, 
cancer and diabetes. By offering tests directly to the public, healthcare providers are bypassed by 
people who are ordering and receiving test results. Without proper explanation and informed 
consent, there is an increased chance that lay individuals will misunderstand their test results 
(Gollust et al. 2003). The companies state that they do not provide medical advice based on their 
test results (23andMe 2011; deCODEme 2011; Pathway Genomics 2011). One area where 
companies differ is the extent to which they offer genetic counseling and whether it is performed 
by a board certified/eligible genetic counselor. While companies with genetic counselors may 
provide genetic counseling to individuals purchasing tests, the companies without genetic 
counselors direct patients back to their personal physician, who may not have the knowledge or 
time to interpret the test results (Baars et al. 2005; Caulfield 2001; Evans et al. 2010; Greendale 
and Pyeritz 2001; Swan 2010; Williams-Jones 2003). 
Currently, there is a dearth of information about healthcare providers’ awareness, experience and 
perceptions of personal genome testing. Ohata and colleagues (2009) assessed general 
practitioners’ awareness of, and opinions about direct-to-consumer (DTC) genetic tests that can 
predict an individual’s susceptibility to certain adult onset diseases. These researchers found that 
38% of general practitioners were aware of DTC genetic testing, primarily from the media, 
scientific meetings/journals, and the Internet. Less than 1% had ordered a DTC genetic test on a 
patient. Physicians listed several benefits and some concerns regarding the testing. Noted 
benefits included convenience, promotion of preventive medicine, providing personalized 
services, and confidentiality of information. Concerns regarding DTC genetic testing included 
the reliability of test results, provision of adequate information/counseling, potential 
misunderstanding of results, inappropriateness of advertising, discrimination in employment and 
insurance, the possible spread of beliefs such as genetic determinism, and the inappropriate 
disclosure of patients’ genetic information. 
Kolor and colleagues (2009) reported results from the 2008 DocStyles survey which was sent to 
internists, family physicians, pediatricians, obstetricians/gynecologists, dermatologists and 
registered dieticians in the US. These researchers found that less than half (42%) of respondents 
were aware of personal genome tests offered directly to consumers. Practitioners most often cited 
the media and the Internet as their source of information about personal genome tests, with 
medical or scientific journals being a secondary source of information. Less than half of their 
healthcare provider respondents who were aware of personal genome testing had discussed test 
results with their patients within the last year or interacted with a patient who had questions 
about personal genome tests. 
Both of these studies surveyed a broad range of healthcare providers at the national level, which 
could obscure regional differences in attitudes, awareness, and the use of personal genome 
testing. 
Purpose of the Present Study 
In this study, North Carolina primary care physicians (PCP) were surveyed to assess their 
awareness, experience and opinions regarding personal genome testing. Participating PCPs were 
limited to family physicians and internists because personal genome tests are marketed to healthy 
adults and generally screen for common diseases seen most frequently in these practice settings. 
The aims of this study were to assess North Carolina PCPs': 1) awareness, 2) experience, 3) 
preparedness to answer patient questions, and 4) opinions regarding the perceived clinical 
usefulness of personal genome testing. 
Methods 
Participants 
A convenience sample of family physicians and internists who were members of the North 
Carolina Medical Society (NCMS) were recruited to participate. The NCMS is the state’s largest 
physician organization with more than 12,000 members (North Carolina Medical Society 2011). 
Members include medical students, residents, practicing physicians, retired physicians, and 
physician assistants. A publically available list containing physician names, medical practice and 
office addresses was obtained from the NCMS website. Of the 12,000 NCMS members, 1,349 
are family medicine providers, and 1,301 are internal medicine providers. Addresses were 
confirmed and/or updated through a Google search using the physician’s name, medical practice, 
and/or the city in which the practice was located. Of the 2,650 family and internal medicine 
providers mentioned above, 2,402 addresses were confirmed. 
Instrumentation 
A novel survey consisting of 30 questions was created by the investigators to meet the goal of 
this project (Appendix A). Eighteen questions were multiple-choice, seven were dichotomous 
items (yes/no), three were fill-in-the-blank, and two were in the form of a Likert-type rating 
scale. Six questions were drawn, with permission, from the 2008 DocStyles survey developed by 
the Centers for Disease Control and Prevention (CDC). A description of personal genome testing 
was adapted from the DocStyles survey, and provided in the introduction. It read: “Genetic tests 
that scan a person’s entire genetic makeup for potential health risks are currently being marketed 
directly to consumers by several different companies (e.g., 23andMe, deCODEme, Navigenics).” 
Respondents were told that the term “DTC genetic test” would be used as a shorthand way to 
describe this service. 
The survey was divided into six sections. Questions from the DocStyles survey were placed in 
four sections that assessed the PCP’s 1) awareness of DTC genetic testing, 2) experience with 
patients discussing/bringing in results from DTC genetic tests, 3) opinions about DTC genetic 
testing, including “perceived clinical usefulness,” and 4) medical management (follow-up) after 
DTC genetic testing. The remaining sections assessed the PCPs’ preparedness to answer 
questions about DTC genetic testing, and participant demographics. Each section consisted of 2–
8 questions, and contained a skip pattern that would allow respondents to skip over questions that 
were not applicable. The survey was piloted with 10 family medicine and internal medicine 
physicians practicing in Greensboro, NC. No modifications were made. 
This study was approved by The University of North Carolina at Greensboro’s Institutional 
Review Board. 
Procedures 
The physicians and surveys were numbered and a unique ID was created. Cover letters, surveys, 
informed consent, and a self-addressed stamped envelope (SASE) were mailed to all family 
practitioners and internists with confirmed addresses. Several tactics were used in the cover 
letter, to help increase participation in the survey. They included: 1) provision of information 
about the survey, 2) a request for help or advice, 3) showing positive regard by personalizing the 
salutation (e.g., Dear Dr. Smith), and 4) saying thank you (Dillman et al. 2009). While no 
compensation was provided to respondents, they were offered a copy of the results once the 
survey was completed (Dillman et al. 2009; Lydeard 1996). Other tactics used to maximize 
survey response included providing alternative ways to return the survey such as a fax number 
and a link to an online version of the survey housed on Zoomerang, an online survey tool. 
Physicians completing the survey online were asked to enter their survey number to avoid 
duplication. When a survey was returned, the physician’s name and address were deleted from 
the key. 
Two reminders were sent to non-responders at three-week intervals. The first reminder was a 
postcard which referenced the online link. The second reminder contained a cover letter, survey 
and SASE. Data collection occurred between January and May, 2010. 
Data Analysis 
Information from the returned surveys was entered into Zoomerang. Data analysis was 
conducted using PASW Statistics version 18.0 (Chicago, IL). The respondents’ personal 
characteristics and survey responses relating to self-reported awareness, self-reported experience 
with patients, physician opinion of DTC genetic testing, and preparedness to answer questions 
about DTC genetic testing were described with frequencies and percentages. The ages of 
participants was collected within five categories: ≤30, 31–40, 41–50, 51–60, and >60. The age 
variable was collapsed into three categories. The variable ≤30 and 31–40 was collapsed to ≤40 
(younger and less experienced PCPs), the variable 41–50 (middle-aged and moderately 
experienced PCPs) and 51–60 and >60 was collapsed to ≥51 (older and more experienced PCPs). 
Board specialty was dichotomized into “family medicine” and “internal medicine” and work 
setting was dichotomized into “private practice” and “other.” Responses to all dependent 
variables (physician awareness, physician preparedness, and perceived usefulness of DTC 
genetic testing) were categorized yes and no. 
Bivariate associations between each physician’s personal characteristic variables and physician 
awareness, preparedness, and perceived usefulness of DTC genetic testing were calculated using 
cross-tabulations. Odds ratios were calculated along with a 95% confidence interval in order to 
explore the strength of the association between the individual predictors and the three outcome 
variables. 
The dichotomous outcome variables of physician awareness, physician preparedness, and clinical 
usefulness were modeled as a function of independent variables for specific respondent personal 
characteristics. For all outcome variables, the initial model was formulated by including all of the 
covariates provided in Table 1. In order to reduce the initial model to the final reduced model, 
odds ratio (OR) estimates were used for all personal characteristics that were shown to be 
predictors of awareness, preparedness, and clinical usefulness. Covariates that were not 
statistically significant predictors of awareness, preparedness, and clinical usefulness were 
eliminated from the full model using a step-wise forward regression procedure in a manner that 
subtraction of the covariates from the model did not alter the odds ratio between any of the 
predictors and the outcome variable by more than 20%. Based on analysis, age and years in 
practice were found to be significantly correlated (Pearson r = 0.487, p = 0.00). Age has a 
stronger correlation to years in practice, therefore years in practice was eliminated from the 
model. The aim of this methodology is to identify the strongest simplified model of respondents’ 
personal characteristics associated with the three identified outcome variables. Multivariate 
adjusted ORs and their 95% confidence interval (CI) were determined by exploring 
log ORs from the multivariate logistic regression using a forward stepwise likelihood ratio 
model.  
Table 1 Personal characteristics of respondents (N = 382) 
Personal characteristics Total 
n % 
Gender 
 Male 263 69.6 
 Female 115 30.4 
Age 
 ≤40 years old 157 41.5 
 41–50 years old 147 38.9 
 ≥51 years old 74 19.6 
Board specialtya 
 Family medicine 205 54.7 
 Internal medicine 123 32.8 
 Other 47 12.5 
Work setting 
 Private practice 211 70.3 
 Other 34 11.3 
 Academic medical center or medical school 28 9.3 
 Community hospital 19 6.3 
 Medical center not affiliated with university 8 2.7 
Years in practice 
 ≤10 years 62 20.7 
 More than 10 years 237 79.3 
a n’s do not sum to the total sample size due to missing data 
Results 
Survey Characteristics 
As per the eligibility criteria, surveys were sent to 2,402 PCPs in North Carolina. Fifty surveys 
were “returned to sender,” resulting in 2,352 eligible respondents. In total, 397 surveys were 
returned to the researchers. Surveys were excluded from the final analysis if they were returned 
blank (n = 10) or the PCP was retired (n = 5), resulting in 382 completed surveys. The usable 
response rate for this study was 16.2% (382/2,352). 
Respondents had the option of returning the survey by mail, fax, or completing it on-line. Of the 
surveys completed, 95.3% were returned by mail (n = 364) and 4.7% were completed on-line 
(n = 18). No respondents returned the survey by fax. Respondent demographics are summarized 
in Table 1. A total of 382 respondents who completed and returned the survey were included in 
the final analysis. A post-hoc analysis was conducted to determine statistical power given the 
sample size of 382 which was 0.80. 
Sample Demographics 
Approximately two-thirds of the respondents were males (69.6%, n = 263). More than half were 
41 years of age or older (58.5%, n = 221). Similarly, 54.7% (n = 205) of the respondents were 
boarded in family medicine, 32.8% (n = 123) were boarded in internal medicine and 12.5% 
(n = 47) were boarded in other specialties such as pediatrics, geriatrics, etc. Most of the 
respondents (70.3%, n = 211) worked in a private practice setting, and the majority 
(79.3%, n = 237) had been in practice more than 10 years (Table 1). The average number of 
years in practice as a physician was 21.8 (SD = 11.7). 
PCP Awareness of DTC Genetic Testing 
Most of the respondents (61.3% n = 234) had never heard or read about DTC genetic testing 
(Table 2). Of those who had heard or read about DTC genetic testing (n = 148), the most 
common sources of information were medical or scientific journals (35.1%, n = 52), television 
(33.1%, n = 49), a newspaper article (28.4%, n = 42) and the Internet (27.0%, n = 40) (Table 2). 
Respondents could indicate more than one answer, and a majority (64.2%, n = 95) marked at 
least two sources of information. There was a strong positive association between respondent age 
and awareness of DTC genetic testing. Respondents 41–50 years old and 51 years of age and 
older were almost twice as likely to be aware of DTC genetic testing compared to those who 
were 40 years of age and younger (Table 3). Bivariate association was examined between work 
setting and awareness but no statistically significant associations were found. A multivariate 
logistic regression analysis using a forward stepwise likelihood ratio model indicates that only 
the PCPs’ age was a significant predictor (p = .01) of respondent awareness of DTC genetic 
testing; this finding is similar to bivariate analysis results (Table 4).  
Table 2 Primary care providers’ awareness, concerns and preparedness regarding DTC genetic 
testing (N = 382) 
  n % 
Self-reported awareness of PCPs 
 Heard or read about DTC genetic testing 
  Yes 148 38.7 
  No 234 61.3 
 Sources PCPs are exposed to for DTC genetic testing 
  Not exposed to any source 235 61.5 
  Exposed to one or more sources 147 38.5 
   Medical or scientific journal 52 35.1 
   Television 49 33.1 
   Newspaper article 42 28.4 
   Internet 40 27.0 
   Magazine article 34 23.0 
   Patients 32 21.6 
   Professional or scientific meeting 26 17.6 
   Professional organization 25 16.9 
   Directly from a company selling DTC genetic testing 20 13.5 
   Radio 17 11.5 
   Health professional 12 8.1 
   Other 8 5.4 
Concerns about DTC testing 
 Patient anxiety 129 87.1 
 Patients incorrect interpretation of results 126 85.1 
 Misleading advertisements 126 85.1 
 Clinical utility questionable 121 81.8 
 Health insurance discrimination 115 77.7 
 Employment discrimination 95 64.2 
 Obligation to refer to a specialist (unnecessarily) 90 60.8 
 Obligation to refer for follow-up procedures (unnecessarily) 90 60.8 
 Inadequate counseling 75 50.7 
 Analytical validity/accuracy questionable 74 50.0 
 Confidentiality of genetic information 67 45.3 
 Other 8 5.4 
Preparedness about DTC genetic testing a 
 PCP preparedness about genetic testing     
  Yes 57 15.0 
  No 323 85.0 
a n’s do not sum to the total sample size due to missing data 
Table 3 Bivariate analysis (unadjusted odds ratios) of primary care providers’ 
personal/professional characteristics with awareness, feeling of preparedness, and ratings of 
clinical usefulness of DTC genetic testing 
Physician personal/professional 
characteristics 
Awareness 
(n = 378) 
Preparedness 
(n = 376) 
Clinical usefulness 
(n = 148) 
Odds 
ratio 
95% 
CI 
Odds 
ratio 
95% 
CI 
Odds 
ratio 
95% 
CI 
Gender 
 Female (reference) – – – – – – 
 Male 1.11 0.71, 
1.75 
2.65a 1.26, 
5.61 
0.54 0.26, 
1.10 
Age 
 ≤40 years old (reference) – – – – – – 
 41–50 years old 1.96a 1.22, 
3.14 
1.29 0.66, 
2.53 
1.43 0.67, 
3.04 
 ≥51 years old 1.99a 1.12, 
3.52 
2.46a 1.20, 
5.08 
0.71 0.28, 
1.78 
Board specialty 
 Internal medicine (reference) – – – – – – 
 Family medicine 0.81 0.51, 
1.28 
0.80 0.42, 
1.52 
3.30a 1.52, 
7.13 
Work setting 
 Other (reference) – – – – – – 
 Private practice 1.01 0.61, 
1.68 
0.59 0.30, 
1.13 
1.76 0.76, 
4.08 
aSignificant at p < .05 
Table 4 Logistic regression—predictors of awareness, clinical usefulness and preparedness of 
DTC genetic testing by participant characteristics 
Participant characteristics β Odds ratio (95% CI) p 
Awareness 
 Age 
  40-years-old or less (reference) – –   
  41–50-years-old 0.505 1.657 (0.922, 2.979) 0.09 
  51 years-old and older 0.852 2.344 (1.187, 4.630)a 0.01 
Clinical usefulness 
 Gender 
  Female (reference) –     
  Male −1.016 0.362 (0.132, 0.993)a 0.04 
 Specialty 
  Internal medicine (reference) – –   
  Family Medicine 0.963 2.618 (1.073, 6.389)a 0.03 
Preparedness 
 Age 
  40-years-old or less (reference) – –   
  41–50-years-old −0.167 0.846 (0.344, 2.080) 0.71 
  51 years-old and older 1.032 2.806 (1.208, 6.515)a 0.01 
aSignificant at p < 0.05 
PCP Experience with Patients 
A majority of the PCPs who were aware of DTC genetic testing (81.1%, n = 120) had never 
discussed DTC tests with a patient or had a patient bring in results of DTC genetic tests 
(Table 5). Only 18.9% (n = 28) of PCPs had at least one patient ask about DTC genetic testing 
(mean = 3 patients, SD = 2.4) and only five PCPs had at least one patient bring in test results 
(mean = 2 patients, SD = 0.713). Additionally, the number of patients asking questions or 
bringing in DTC genetic test results comprised significantly less than 10% of the PCPs’ patient 
population. Respondents were given a list of types of patient questions and instructed to indicate 
which of these their patients have asked them. Frequencies of each category of questions that 
were asked of physicians are listed in Table 6.  
Table 5 Experience and perceived clinical utility of DTC genetic testing among those primary 
care providers who are aware of testing (n = 148) 
  n % 
Self-reported experience with patients 
 Had patients ask about and/or bring in results of DTC genetic testing 
  Yes 28 18.9 
  No 120 81.1 
  Number of patients who asked questions about or brought in results from DTC genetic testing 
in the past yeara 
   ≤2 patients 16 57.1 
   More than 2 patients 12 42.9 
Clinical Utility DTC genetic testing 
 Feel that DTC testing is clinically useful 
  Yes 63 42.6 
  No 85 57.4 
 Rating of clinical usefulness of DTC Genetic Testingb,c 
  Very useful 3 5.1 
  Useful 4 6.8 
  Somewhat useful 50 84.7 
  Not useful 2 3.4 
 PCPs rating on likelihood that DTC test results would influence patient carec 
  Very likely 7 4.8 
  Likely 50 34.0 
  Unlikely 70 47.6 
  Very unlikely 20 13.6 
aFrequency is based on the number of patients who asked and/or brought results of DTC genetic 
testing bFrequency is based on the number of PCPs who feel that DTC testing is useful c n’s do 
not sum to the total sample size due to missing data 
Table 6 Categories of questions patients asked to respondents about DTC genetic testing 
Question category n (27)a % 
What you know about the test(s) 20 74.1 
Whether you think the patient is at risk for a particular disease 14 51.8 
What you know about the benefits of testing 14 51.8 
What you would do in their situation 12 44.4 
How the test results may change your patient’s care 7 25.9 
What you know about the (company/companies) that are offering the test 6 22.2 
Whether the cost is appropriate for the type of information they will obtain 6 22.2 
Other 1 3.7 
aNumber of respondents answering the question; total n >100 because respondents could endorse 
multiple questions 
The most frequent conditions for which patients brought in DTC genetic test results to discuss 
with their physicians were cancer (n = 4), cardiac disease (n = 3), neurological diseases (n = 3), 
and single gene disorders (n = 3). No respondent remembered which DTC testing company the 
patients had used for testing. 
Follow-up Activities by PCPs Who are Aware of DTC Testing 
This section of the survey assessed PCPs follow-up medical management plans for patients who 
brought in DTC genetic test results. Four of the five PCPs who had patients bring in results 
reported they did not change their patient’s medical management, while the remaining physician 
recommended lifestyle changes including changes in diet and supplements. Reasons given for 
choosing not to change patient care were that the test did not indicate the patient was at increased 
risk for developing the disease (n = 1) or that there were no evidence-based medical guidelines 
respondents could follow that would prevent the disease (n = 3). Respondents were asked to 
choose one answer. 
PCP Opinions Regarding Clinical Usefulness 
Almost half of the respondents who were aware of DTC genetic testing (42.6%, n = 63) thought 
that testing was clinically useful when formulating medical management plans. Among the PCPs 
who indicated DTC genetic testing was clinically useful at some level, the majority 
(84.7%, n = 50) thought it was somewhat useful (Table 5). 
The 63 respondents who indicated DTC genetic testing was clinically useful were asked about its 
clinical benefits. The most frequently endorsed benefits were the ability to: 1) offer screening 
tests (e.g., mammograms, colonoscopies, EKG) at an earlier age to individuals at an increased 
risk (82.5%, n = 52), and 2) offer screening tests more frequently to individuals who are found to 
be at an increased risk (81.0%, n = 51). 
The 85 respondents who were aware of DTC genetic testing and indicated that it is not clinically 
useful endorsed these reasons: 1) no guidelines exist to reduce or alleviate the risk for many 
diseases (80.0%, n = 68), 2), it is too difficult to interpret what the results mean regarding patient 
care (58.8%, n = 50), 3), it will cause more patient anxiety (51.8%, n = 44), 4), they would not 
change a patient’s management based on DTC testing (35.3%, n = 30), or 5) “Other” 
(18.8%, n = 16). “Other” reasons fell into the following categories: the lack of clinical usefulness 
of results (n = 6), the lack of accuracy of the test results (n = 6), and concerns about future 
insurance coverage for a patient who had DTC genetic testing (n = 4). 
Of the five respondents who had a patient bring in results, four respondents indicated that DTC 
genetic testing was not clinically useful. These four endorsed the following reasons: no 
guidelines exist to reduce or alleviate the risk for many diseases (n = 4), it is too difficult to 
interpret what the results mean regarding patient care (n = 3), and it will cause more patient 
anxiety (n = 2). None of the four endorsed the comment “I would not change a patient’s 
management based on DTC testing”. 
Primary care providers who were aware of DTC genetic testing were also asked what concerns 
they have about the testing. From a list of 12 concerns (Table 2), the most common concerns 
included that: results could increase patient anxiety (87.1%, n = 129), patients may interpret the 
results incorrectly (85.1%, n = 126), advertisements may mislead patients (85.1%, n = 126), and 
the clinical utility is questionable (81.8%,n = 121). 
When asked how likely it was that a patient’s DTC genetic test results would influence their care 
of a patient, those respondents who were aware of DTC genetic testing (n = 148, 38.8%) felt 
DTC genetic test results were likely (33.8%, n = 50) or very likely (4.7%, n = 7) to influence the 
care of patients in their practice (Table 5). A majority of the PCPs (74%, n = 42) who thought 
that DTC testing was likely or very likely to influence care also felt the results were clinically 
useful. A strong positive association was obtained between the PCP’s specialty and their 
opinions about the clinical usefulness of DTC genetic testing. Primary care providers who were 
practicing family medicine were three times as likely to think DTC genetic testing is clinically 
useful compared to PCPs who were practicing internal medicine (Table 3: OR = 3.3; CI = 1.52–
7.13). In a multivariate logistic regression analysis, using a forward stepwise likelihood ratio 
model, PCP gender (p = .04) and specialty (p = .03) (Table 4) of the PCP were found to be of 
significant predictive value for determining respondent’s opinion regarding the clinical 
usefulness of DTC genetic testing. Regression analysis results for gender were not similar to the 
bivariate analysis findings. 
PCP Preparedness to Answer Questions About DTC Genetic Testing 
A majority of the respondents (85%, n = 323) did not feel prepared to answer their patient’s 
questions regarding DTC genetic testing (Table 2). A strong positive association was obtained 
between the PCP’s gender and their sense of preparedness in answering questions about DTC 
genetic testing. Male PCPs were twice as likely to feel prepared to answer questions about DTC 
genetic testing compared to female PCPs (Table 3; OR = 2.65; CI. = 1.26–5.61). A strong 
positive association was detected between respondents’ age and preparedness. Primary care 
providers ≥51 years of age were more than twice as likely to feel prepared to answer questions 
about DTC genetic testing compared to younger PCPs (Table 3; OR = 2.46; CI = 1.20–5.08). A 
positive correlation was found between a sense of preparedness and awareness about DTC 
genetic testing (Pearson r = .259, p = .01) and age (Pearson r = .123, p = .01). No significant 
findings were obtained associations for bivariate associations with work setting and 
preparedness. A multivariate logistic regression analysis using a forward stepwise likelihood 
ratio model was performed to determine predictors of preparedness. Only PCP age was found to 
be of a significant predictor (p = .01) (Table 4) of preparedness to answer questions about DTC 
genetic testing. Primary care providers who were ≥51 years of age were significantly more likely 
to say they were prepared to discuss DTC genetic testing than those who were ≤40 years of age. 
Discussion 
This is the first regional survey in the United States of primary care physicians concerning their 
awareness and attitudes about DTC genetic testing. Primary care providers were specifically 
targeted because 1) it is anticipated that patients in adult primary care offices will increasingly 
ask questions, or bring in results from this type of genetic testing, 2) DTC genetic testing 
companies target their tests toward healthy adults, and 3) the conditions companies test for, with 
few exceptions, are common complex diseases that typically have an adult onset. The present 
results indicate that approximately 39% of respondents were aware of DTC genetic testing. Their 
awareness level and sources of information are similar to those reported previously in the 
literature (Kolor et al. 2009; Ohata et al. 2009). 
While the overall awareness level of DTC genetic testing in this study was similar to other 
studies, the level of PCP experience with patients inquiring about DTC genetic testing was 
substantially lower. Only 18.9% (n = 28) of PCPs who were aware of DTC genetic testing had 
ever answered questions or discussed DTC test results with their patients compared to 42% of 
providers in a national sample of US providers (Kolor et al.2009). When looking at how much 
first-hand experience PCPs in this study had, on average they answered questions from three 
patients or discussed DTC genetic testing from two patients. These results suggest that, at this 
time, a minority of North Carolinians may be pursuing DTC personal genome testing or, if they 
are pursuing testing, that they are not discussing the results with their primary care physicians. 
This is consistent with other reports indicating a low demand (an estimate of 20,000–30,000 tests 
purchased world wide from one of the three companies offering DTC genetic testing in 2009) for 
DTC genetic testing on a national level (2009 by the numbers 2009; Pollack 2010; Wright and 
Gregory-Jones 2010). The low patient interest in DTC genetic testing may also reflect the fact 
that North Carolina has a relatively low household median income level (41st in the country) 
(U.S. Census Bureau 2009). Therefore, since this testing is typically not covered by insurance, 
North Carolina residents may lack the disposable income to pay for this type of testing. 
Almost half of the responding PCPs who were aware of DTC genetic testing felt that it was at 
least somewhat clinically useful for formulating medical management plans. Therefore, if a PCP 
feels the test is clinically useful then it is likely the results will influence medical management. 
Despite a lack of guidelines on how to manage patients based on DTC test results, the ability to 
offer screening tests more frequently and at earlier ages to those who test positive for adult onset 
diseases were often endorsed as benefits of the tests. Overall, family practice PCPs were 
significantly more likely to believe that this technology is clinically useful. One plausible 
explanation may be that family practice physicians focus on disease prevention and health 
promotion, which is one of the primary goals of genomic medicine, whereas internists tend to be 
skilled in the management of patients who have undifferentiated or multi-system disease 
processes (American Academy of Family Physicians 2006). 
Respondents’ concerns about patient anxiety, the potential for misinterpretation, and misleading 
advertising are consistent with those reported in other studies (Ohata et al. 2009), and by 
professional societies (American College of Medical Genetics (ACMG) 2008; American Society 
of Human Genetics (ASHG) 2007; National Society of Genetic Counselors (NSGC) 2007), 
governmental agencies (Kutz 2010; Secretary Advisory Committee on Genetic Testing 2008) 
and advocacy groups (Genetic Alliance 2005). National genetic organizations and advocacy 
groups have called for personal genome companies to provide relevant information about their 
tests in an easily accessible and understandable format. This includes providing information to 
the consumer on the clinical validity and utility of the tests, credentials of the laboratories 
performing the tests, how patient privacy is maintained and how to access a knowledgeable 
healthcare provider for interpretation of results (ACMG 2008; ASHG 2007; Genetic 
Alliance 2005; NSGC 2007). 
Other concerns were also noted by survey respondents. Despite a lack of evidence of genetic 
discrimination (Billings et al. 1992), and the fact that the Genetic Information Non-
Discrimination Act went into effect in 2009 (Genetic Information Nondiscrimination Act 
of 2008), most respondents were concerned about health insurance and employment 
discrimination. Therefore, important discussion points to include in a PCP education program are 
the risks of insurance and employment discrimination as well as legislation currently in place to 
protect against genetic discrimination. 
Studies have indicated that patients will seek out their primary care provider to discuss their 
genetic test results and obtain the appropriate follow-up care (Burke 2004; Holtzman and 
Watson 1997; Miller et al. 2010; Morren et al. 2007). Similarly, at least one study has suggested 
that individuals undergoing personal genome testing expect their physician to help interpret the 
results (McGuire et al. 2009), and DTC companies direct patients to their physician to discuss 
the test results before acting upon the genetic testing information (23andMe 2011; 
deCODEme 2011; Pathway Genomics 2011). Therefore, PCPs are most likely going to shoulder 
the responsibility for discussing this technology with their patients. However, the majority of 
respondents in this survey indicated they did not feel prepared to answer patient questions (e.g. 
preparedness) about DTC genetic testing. Similar findings are reported in the literature, as 
several studies have found that PCPs generally have a lack of knowledge about genetics, genetic 
testing and genetic counseling (Greendale and Pyeritz 2001; Guttmacher et al. 2001; Suther and 
Goodson 2003). Since whole genome scanning is a newer technology, PCPs’ knowledge of this 
topic may be low, resulting in a lack of confidence in assessing risk or managing care. 
Study Limitations 
Several aspects of this study may have limited generalizability of the findings. In particular, the 
fact that this is a convenience sample of PCPs, and there was a low response rate (16.2%), it 
cannot be determined how representative the survey respondents are of the general PCP 
population in North Carolina. However, this study does provide preliminary findings for a larger 
comprehensive study. The literature indicates that surveys of general practitioners generally 
achieve poor response rates (McAvoy and Kaner 1996). Possible reasons for the low response 
rate include 1) lack of monetary incentives, 2) the mailed survey was four pages, printed front 
and back and appeared long, and/or 3) the topic was not of current clinical interest to the PCP 
population. The gender demographics of this survey resembles the gender distribution of the 
NCMS membership (i.e. 66% and 73% males in family practice and internal medicine, 
respectively); these are which is the only demographic characteristics we could compare as the 
NCMS did not respond to requests for information concerning other demographic characteristics 
of their members. 
Another limitation is that we could not determine the extent to which respondents used a 
particular resource to obtain information about DTC testing. For instance, some respondents may 
have had multiple exposures to different sources of information while others had a single 
exposure. In addition, some may have had brief exposures while others may have researched the 
topic in more detail. Differences between the various resources may determine whether a PCP 
feels that explaining DTC genetic testing is easy or complicated. Therefore, one area of future 
research is to compare and contrast the accuracy and depth of the messages within information 
sources. 
Finally, survey respondents could have misunderstood the type of genetic testing that was the 
focus of this study. Efforts were made to indicate that the questions pertained to personal genome 
tests available directly to consumers. However, some questions only included the wording “DTC 
genetic testing” and respondents could have thought these items referred to any DTC genetic 
testing (e.g., nutrigenomic genetic testing) or genetic tests where DTC marketing is performed 
(e.g., Myriad’s BRAC Analysis). This confusion could have influenced their responses, thereby 
raising questions about the validity of the data obtained. 
Clinical Implications 
Despite the limitations of this study, the findings have implications for clinical practice. Should 
DTC genetic testing become more widely used, a comprehensive education program may be 
necessary to increase PCP awareness of DTC genetic testing and help PCPs discuss testing with 
their patients. Based on the concerns indicated by the respondents, topics to include in an 
education initiative are guidelines on how to manage patients at increased risk for common 
disease, information on how to communicate results without unnecessarily increasing patient 
anxiety, the clinical utility of DTC genetic testing, privacy issues, and patient concerns 
surrounding health insurance and employment discrimination. Access to genetic counseling may 
help alleviate some of these concerns. A genetic counselor, or other qualified health professional, 
can discuss the pros and cons of the test, thus assisting consumers in recognizing both the utility 
and limitations of personal genome tests (American Society of Human Genetics 2007). 
Research Recommendations 
This study focused solely on physicians. Other health care professionals, such as physician 
assistants and nurse practitioners who specialize in primary care, should be surveyed about DTC 
testing. These providers may see their own patients and may have awareness, experiences and 
opinions that are distinctly different from those of physicians. Additionally, investigations of the 
North Carolina consumer population to determine their attitudes and experience with DTC 
genetic testing may provide some insight into who is being tested in North Carolina and whether 
the numbers of individuals being tested is equivalent to those who are talking with their 
providers. 
Another area of research would be to identify all of the factors PCPs would take into 
consideration when preparing management plans based on DTC genetic testing. This study asked 
the question “In general, do you think DTC genetic testing is currently clinically useful, meaning 
you would take a patient’s test results into consideration when formulating your medical 
management plan (e.g., when to refer for screening tests, when to refer to a specialist, etc.)?”. 
Since respondents were only able to answer yes or no, it is unknown what other factors they 
would consider. 
A final area of research that arises from these findings involves the factors that make a PCP 
aware of, and feel prepared to answer questions about DTC genetic testing. In the present study, 
male respondents and those 51 years or older more were more likely to feel prepared to answer 
questions. Research in the area of gender differences indicates that men are encouraged to 
express more assertive and independent behaviors (Heilman 2001), and at least one study has 
indicated the tendency for male physicians to overestimate their competence (Lind et al. 2002). 
Additionally, the respondents in this study who were age 51 years or older (and typically in 
practice longer than younger respondents) were more likely to be aware of DTC genetic testing. 
Development and validation of measures that assess the importance of gender and other factors 
such as confidence gained through years of practice may help identify reasons for these findings. 
Conclusions 
Primary care providers surveyed in a regional area reported similar awareness rates but less 
patient experience than findings of a national survey of providers (Kolor et al. 2009). 
Additionally, most PCPs tended to be skeptical of the clinical utility of DTC genetic testing and 
did not feel prepared to answer patient questions on the subject. Knowledge of DTC genetic 
testing issues may increase PCPs’ comfort and proficiency discussing such testing and deciding 
whether to make changes in a patient’s care plan based on testing results. Education about 
clinical utility, privacy issues, and the pros and cons of testing is needed if DTC genetic testing 
becomes more widely used. Genetic counselors are positioned to play a key role in providing this 
education for PCPs and for consumers. 
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Appendix A: Survey Questions 
Awareness 
Genetic tests that scan a person’s entire genetic makeup for potential health risks and are 
marketed directly to consumers are called direct-to-consumer (DTC) genetic tests. For the 
majority of this survey, we will use the term DTC genetic test to describe this service. 
1) Genetic tests that scan a person’s entire genetic makeup for potential health risks are currently 
being marketed directly to consumers by several different companies (e.g., 23andMe, 
deCODEme, Navigenics). Have you heard or read about these genetic tests? 
a. Yes 
b. No → SKIP TO QUESTION 21 
2) From which of the following sources did you hear or read anything about genetic tests that 
scan a person’s entire genetic makeup for potential health risks (e.g. tests marketed direct to 
consumers such as 23andMe, deCODEme, Navigenics)? Circle all that apply. 
a. Television 
b. Internet 
c. Professional organization 
d. Medical or scientific journal 
e. Patients 
 f. Magazine article 
g. Newspaper article 
h. Health professional 
i. Radio 
j. Professional or scientific meeting 
k. Directly from a company selling DTC genetic testing 
l. Other, please specify:_________________________ 
 Experiences with Patients 
3) Have any patients ever asked questions about or brought in results from DTC genetic tests? 
a. Yes 
b. No → SKIP TO QUESTION 15 
 4) In the past year, how many of your patients asked questions about having a genetic test that 
scans a person’s entire genetic makeup for potential health risks (e.g., 23andMe, deCODEMe, 
Navigenics)? 
a. None→ SKIP TO QUESTION 7 
b. Please put number of patients: ________________ 
 5) What percentage of your total patient population does this make up? Please circle one. 
a. 1–10% 
b. 11–20% 
c. 21–30% 
d. 31–50% 
e. 51–75% 
f. >75% 
 6) Into which of the following categories would you put the questions your patients have asked 
you about DTC genetic testing? Circle all that apply. 
a. I have not had a patient ask questions about DTC genetic testing 
b. What you know about the (company/companies) that are offering the test 
c. What you know about the test(s) 
d. Whether you think the patient is at risk for a particular disease 
e. What you know about the benefits of testing 
 f. How the test results may change your patient’s care 
g. What you would do in their situation 
h. Whether the cost is appropriate for the type of information they will obtain 
i. Other, please specify:________________________  
7) In the past year, how many of your patients brought results from a genetic test that scans a 
person’s entire genetic makeup for potential health risks (e.g., 23andMe, deCODEMe, 
Navigenics) to you for discussion? Please circle one. 
a. None→ SKIP TO QUESTION 15 
b. Please put number of patients: ________________ 
8) What percentage of your total patient population does this make up? Please circle one. 
a. 1–10% 
b. 11–20% 
c. 21–30% 
d. 31–50% 
e. 51–75% 
f. >75% 
 9) What condition(s) have your patients been tested for when they had DTC genetic testing? 
Circle all that apply. 
a. Autoimmune (Graves disease, lupus, psoriasis, rheumatoid arthritis, sarcoidosis, 
inflammatory bowel) 
b. Bone (osteoarthritis) 
c. Cancer (breast, lung, colon, stomach, melanoma, prostate) 
d. Cardiac (atrial fibrulation, heart attack, coronary artery disease) 
e. Endocrine (type 2 diabetes, type 1 diabetes, obesity) 
f. Eye (macular degeneration, glaucoma) 
g. GI (hemochromatosis, Celiac disease, Crohn’s disease, lactose intolerance) 
h. Neurologic (Alzheimer’s, multiple sclerosis, restless leg syndrome) 
i. Pharmacogenomic testing (Genotyping for Warfarin response, Tamoxifen response, 
Oncotype Dx, Psychiatric drug response) 
j. Single gene disorder (familial hypercholesterolemia, cystic fibrosis) 
k. Vascular (abdominal aneurysm, brain aneurysm, DVT) 
l. Not sure/Cannot remember 
m. Other, please specify:________________________ 
 10) What company/companies did your patient/patients use? Circle all that apply. 
a. 23 and Me 
b. DeCodeMe 
c. Navigenics 
d. DNA Direct 
e. I don’t know/I cannot remember 
 f. Other, please specify _______________ 
  Follow-up 
11) Did you ever change any aspect of a patient’s care based solely on the results of his or her 
DTC genetic test? Please circle one. 
a. Yes 
b. No, because none of the tests indicated that a patient was at increased risk for 
disease→ SKIP TO QUESTION 15 
c. No—even though tests indicated that a patient was at increased risk for disease, 
because there were no evidence-based medical management guidelines to follow that 
would reduce their risk or prevent the disease → SKIP TO QUESTION 15 
d. No—for reasons other than those specified above, please explain 
__________________________ → SKIP TO QUESTION 15 
 12) For your patient(s) who brought the results from a genetic test that scanned the person’s 
entire genetic makeup for potential health risks (e.g., 23andMe, deCODEme and Navigenics) to 
discuss with you during an office visit during the past year, which aspects of your patient’s care 
did you change based on the results? Circle all that apply. 
a. Screening tests that you offered 
b. Medications or doses that you prescribed 
c. Lifestyle changes that you recommended 
d. Frequency of follow-up appointments scheduled 
e. Diagnoses that you made 
f. Not sure 
g. No aspects of patient care 
h. Other aspects of patient care, please specify: _______________________________ 
13) Did you refer any patient to a specialist based solely on the results of a DTC genetic test? 
a. Yes 
b. No → SKIP TO QUESTION 15 
14) To whom did you make a referral? Circle all that apply. 
a. Genetic counselor 
b. Geneticist 
c. Cardiologist 
d. Oncologist 
e. Neurologist 
f. Endocrinologist 
g. Gastroenterologist  
h. Dietician 
i. Other, please specify: _____________________ 
Opinions 
15) In general, do you think DTC genetic testing is currently clinically useful, meaning you 
would take a patient’s test results into consideration when formulating your medical management 
plan (e.g. when to refer for screening tests, when to refer to a specialist, etc.)? 
a. Yes → SKIP TO QUESTION 17 
b. No 
16) If no, why do you feel DTC genetic testing is not clinically useful? Please, circle all that 
apply. 
AFTER ANSWERING THIS QUESTION, PLEASE SKIP TO QUESTION 19. 
a. It is too difficult to interpret what the results mean regarding patient care 
b. I would not change a patient’s management based on DTC testing 
c. It will cause more patient anxiety 
d. No guidelines exist to reduce or alleviate the risk for many diseases 
e. Other, please specify:________________________  
17) If yes, how clinically useful do you feel DTC genetic testing currently is? Please circle one. 
a. Very useful 
b. Useful 
c. Somewhat useful 
d. Not useful  
18) Which of the following do you see as a clinical benefit of DTC genetic testing? Circle all that 
apply. 
a. Offering screening tests (e.g. mammograms, colonoscopies, EKG) more frequently to 
individuals who are found to be at increased risk 
b. Offering screening tests (e.g. mammograms, colonoscopies, EKG) at an earlier age to 
individuals who are found to be at increased risk 
c. Changing medication doses 
d. Prescribing medication 
e. Recommending lifestyle changes 
f. Changing the frequency of follow-up appointments 
g. Making a diagnosis 
h. Providing genetic testing in a more private, confidential manner 
i. None of the above 
j. Other, please specify: _______________________  
19) Which of the following concerns you about DTC genetic testing? Circle all that apply. 
a. I do not have any concerns about DTC genetic testing 
b. The analytical validity, or accuracy, of the test results is questionable 
 c. The clinical utility, or ability to use the results in practice, is questionable 
d. Counseling provided by the companies following DTC genetic testing is nonexistent or 
inadequate 
e. Patients may interpret the results incorrectly 
f. Advertisements may mislead patients 
g. Results could lead to discrimination in employment 
h. Results could lead to discrimination in health insurance 
i. Genetic information may not be kept confidential by the DTC testing companies 
j. Results could increase patient anxiety 
k. Physicians may feel obligated to refer patients to specialists, perhaps unnecessarily 
l. Physicians may feel obligated to refer patients for follow-up procedures, perhaps 
unnecessarily 
m. Other, please specify: ______________________  
20) If a patient were to bring the results from a genetic test that scanned the person’s entire 
genetic makeup for potential health risks (e.g., 23andMe, deCODEme and Navigenics) to discuss 
with you during an office visit today, how likely is it that the test results would influence your 
care of the patient? Please circle one. 
a. Very likely 
b. Likely 
c. Unlikely 
d. Very unlikely  
Preparedness 
21) Would/do you feel prepared to answer a patient’s questions about DTC genetic testing? 
a. Yes 
b. No 
 Background Information 
22) What is your gender? 
a. Male  
b. Female 
23) What is your age? 
a. <=30 
b. 31–40 
c. 41–50 
d. 51–60 
e. >60 
24) In which specialty were you boarded? Circle all that apply. 
a. Family medicine 
b. Internal medicine 
c. Pediatrics 
d. Geriatrics 
e. Other, please specify: _____________  
25) How would you describe your work setting (if you have appointments at more than one 
setting, please answer these questions thinking of your primary institution)? Please circle one. 
a. Academic medical center or medical school 
b. Medical center not affiliated with a university 
c. Community hospital 
d. Private practice 
e. HMO 
f. Other, Please specify: _______________________ 
26) How many years have you been practicing as a physician? (please specify in whole years, 
rounding up to the nearest year) ______ years 
Thank you for taking this survey! 
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